Focused On-demand Library for Prolyl 4-hydroxylase subunit alpha-3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q7Z4N8

UPID:

P4HA3_HUMAN

Alternative names:

Procollagen-proline,2-oxoglutarate-4-dioxygenase subunit alpha-3

Alternative UPACC:

Q7Z4N8; A0AV13; B4DUD3; Q5EBL3; Q5JPA9

Background:

Prolyl 4-hydroxylase subunit alpha-3, also known as Procollagen-proline,2-oxoglutarate-4-dioxygenase subunit alpha-3, plays a crucial role in the biosynthesis of collagens. It catalyzes the post-translational formation of 4-hydroxyproline in -Xaa-Pro-Gly- sequences, a modification essential for the stability and function of collagen molecules.

Therapeutic significance:

Understanding the role of Prolyl 4-hydroxylase subunit alpha-3 could open doors to potential therapeutic strategies. Its pivotal function in collagen synthesis makes it a target of interest in diseases related to connective tissue and extracellular matrix disorders.